eHealth (NasdaqGS:EHTH) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsDerrick Duke - CEOJohn Dolan - CFOConference Call ParticipantsGeorge Sutton - Senior Research AnalystJonathan Yong - Equity Research AnalystMax Young - Equity Research AnalystMichael Murray - Equity Research AnalystOperatorGood afternoon, everyone, welcome to eHealth, Inc. conference call to discuss the company's Q4 and fiscal year 2025 financial results. At this time, all participants have been placed in listen- ...

Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share of $3.98, up 30.8% [6][24] - In Q4 2025, revenue reached $826.4 million, growing 25.7% compared to Q4 2024, with non-GAAP EPS at $1.28, a 52.1% increase [7][25] - The adjusted gross margin for Q4 was 69.2%, compared to 67.1% in the prior year quarter, driven by favorable sales mix and synergy execution [30][31] Business Line Performance - The U.S. spine business grew 10% in Q4 2025 compared to the prior year quarter, continuing a trend of above-market growth [8][28] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [12][27] - The trauma business delivered approximately 27% growth in Q4, supported by the legacy trauma line and new product launches [16][17] Market Performance - U.S. revenue in Q4 2025 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, growing 19% [27][28] - The international spine business faced challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [29][83] Company Strategy and Industry Competition - The company aims to expand its core spine business while growing other segments, positioning itself as a procedure-enabling medtech platform integrating imaging, navigation, robotics, and implants [19][20] - The competitive landscape is evolving, with new robotic navigation systems entering the market, but the company believes its ExcelsiusGPS system remains a strong option for customers [13][73] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in sustained growth momentum, particularly in the U.S. spine business, and anticipates continued above-market growth in 2026 [9][71] - The company expects to achieve a full-year adjusted gross margin of 69%-70% in 2026, reflecting ongoing improvements in manufacturing initiatives [32][43] Other Important Information - The company repurchased approximately 4.3 million shares for $300.5 million during 2025, with a new share repurchase program of $500 million announced [39] - Full-year 2025 SG&A expenses were $1.178 billion, or 40% of sales, with expectations for 2026 to be in the range of 38%-39% [36] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [49][50] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [58] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [62][63] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [71][72] Question: What are the headwinds in the international market? - Management identified challenges in the APAC region, particularly Japan, but believes there are ample opportunities for growth in existing markets [82][83]

Company Overview - LivaNova is a global medtech company with approximately $1.3 billion in revenue over the last 12 months as of September of the previous year, boasting nearly five decades of experience in the industry [4]. Recent Developments - The company has seen improvements in reimbursement for its Epilepsy business, which is a significant positive development [2]. - CORE-VNS data was presented at the American Epilepsy Society, highlighting advancements in the company's offerings [2]. - A manuscript covering durability data for the RECOVER study in difficult-to-treat depression has been published, indicating ongoing research and development efforts [2].

Core Insights - Ingredion Incorporated reported a decline in both net sales and adjusted earnings per share (EPS) for Q3 2025 compared to Q3 2024, with reported EPS at $2.61 and adjusted EPS at $2.75, down from $2.83 and $3.05 respectively [2][4][22] Financial Performance - Net sales for Q3 2025 were $1.816 billion, a decrease of 3% from $1.870 billion in Q3 2024, primarily due to changes in pricing mix and reduced sales volume in the Food & Industrial Ingredients segments [6][40] - Reported operating income for Q3 2025 was $249 million, down 7% from $268 million in Q3 2024, while adjusted operating income was $254 million, a 10% decrease from $282 million [9][40] - The company expects full-year 2025 reported EPS to be in the range of $11.11 to $11.31, and adjusted EPS to be between $11.10 and $11.30 [4][22] Segment Performance - The Texture & Healthful Solutions segment saw a slight increase in net sales to $605 million, up 1% from $600 million in Q3 2024, driven by strong growth in clean label ingredient solutions [10][40] - The Food & Industrial Ingredients segment in Latin America reported net sales of $585 million, a decline of 6% from $620 million in Q3 2024, attributed to weak demand in the brewing industry and overall consumer demand [13][40] - The U.S./Canada Food & Industrial Ingredients segment experienced a 7% decrease in net sales to $507 million, down from $548 million in Q3 2024, primarily due to production challenges following a fire at a major manufacturing facility [15][40] Strategic Outlook - The company plans to continue investing in organic growth opportunities and acquisitions to enhance its Texture & Healthful Solutions portfolio [4][21] - Ingredion aims to return capital to shareholders through dividends and share repurchases, having paid $54 million in dividends in Q3 2025 [21][23] - The company anticipates low to mid-single-digit growth in both reported and adjusted operating income for the full year 2025 [22][24]

Financial Data and Key Metrics Changes - The company reported a GMV of $1,450,000,000, representing a 34% year-over-year increase, and revenues of almost $215,000,000, up 28% year-over-year [10][23] - Adjusted gross profit for Q2 was just shy of $100,000,000, up 24% from last year, with adjusted EBITDA of $38,500,000, up 23% compared to the same quarter last year, resulting in a 17.9% margin [10][26] - The company achieved GAAP profitability with a net profit of $10,500,000 compared to a net loss of $22,400,000 in the same quarter of last year [10][27] Business Line Data and Key Metrics Changes - Service fee revenue for the quarter was $102,900,000, while fulfillment services revenue was $112,000,000 [23] - The service fee take rate increased compared to Q1 2025, while the fulfillment take rate decreased as expected due to seasonal higher average order value [24] Market Data and Key Metrics Changes - The company continues to see strong growth across many geographies and cohorts of merchants, with notable expansions in the U.S. market [12][78] - The U.S. business has outperformed, driven by strong growth from digitally native brands [78] Company Strategy and Development Direction - The company extended its partnership with DHL for an additional three years, enhancing service offerings for merchants [14] - The acquisition of ReturnGo aims to improve post-purchase solutions for merchants, integrating advanced technology for returns and exchanges [15][49] - The company is focused on enhancing its 3B2C offering to help brands offset costs due to rising tariffs [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business model despite uncertainties around duty tariffs and trade dynamics [9][11] - The company anticipates continued strong trading patterns and does not expect significant impacts from upcoming changes to the U.S. de minimis exemption [11][36] Other Important Information - The company ended the quarter with $516,000,000 in cash and cash equivalents, with free cash flow of $63,500,000 [27] - For Q3 2025, the company expects GMV in the range of $1,455,000,000 to $1,495,000,000, representing a growth rate of 30% versus 2024 [28] Q&A Session Summary Question: Expectations around the de minimis exemption and its impact - Management indicated that they do not expect a significant impact from the removal of the de minimis exemption, noting resilient trading patterns [33][36] Question: Impact of the ReturnGo acquisition on revenue and OpEx - The acquisition is expected to have a slight positive impact on revenue and a minor negative impact on adjusted EBITDA in 2025, with expectations of neutral impact by 2026 [38] Question: Take rate dynamics for the 3B2C product - The take rate for the 3B2C solution is expected to be similar to regular B2C transactions, with minimal impact from clearance fees [45] Question: Growth in the U.S. business and its drivers - The U.S. business is outperforming due to strong growth from digitally native brands, contributing positively to overall performance [78] Question: Contribution from borderfree.com - The borderfree.com platform contributed over 4% of sales from merchants utilizing the service, in line with expectations [87] Question: Trends in NDR and same-store merchant GMV growth - Year-to-date figures are in line with historical averages, with expectations for new merchant contributions to be similar to last year [89]

Financial Data and Key Metrics Changes - Total reported revenue grew by 9% in the first quarter, with constant currency organic revenue increasing by 8% driven by volume and a 30 basis points price increase [6][7] - Gross margin increased by 20 basis points to 45.3%, while EBIT margin rose by 50 basis points to 22.8% of revenue compared to the previous year [7] - Net income from continuing operations was $231.2 million, and adjusted earnings per diluted share improved by 15% to $2.34 [7][8] - Free cash flow for the fiscal year 2026 was reported at $327 million, with a strong start driven by increased earnings and improvements in working capital [8] Business Line Data and Key Metrics Changes - In the Healthcare segment, constant currency organic revenue grew by 8%, with capital equipment revenue increasing by 6% and service revenue growing by 13% [13] - The AST segment saw a 10% growth in constant currency organic revenue, with services growing by 12% and EBIT margins increasing by 150 basis points to 48.6% [14] - Life Sciences group experienced a 4% increase in constant currency organic revenue, driven by an 8% growth in consumables [15] Market Data and Key Metrics Changes - The company reported a backlog of over $400 million in Healthcare capital equipment, indicating strong underlying order growth of 14% [13] - Life Sciences backlog increased by over 50% to $111 million, reflecting a recovery in capital orders after a previous slowdown [15] Company Strategy and Development Direction - The company is focused on maintaining consistent dividend growth, announcing a 10% increase to $0.63 per quarter [8] - Management emphasized the importance of strategic oversight and financial leadership during the CFO transition, indicating confidence in the company's future direction [10][12] - The company is actively pursuing M&A opportunities while also considering stock buybacks to offset dilution [43][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong order growth and backlog, indicating a positive outlook for revenue guidance despite external challenges [41] - The company updated its revenue growth outlook to approximately 8% to 9%, reflecting favorable currency impacts, while maintaining a constant currency organic revenue growth forecast of 6% to 7% [16] - Management acknowledged the challenges posed by increased tariffs and healthcare costs but remained optimistic about the overall demand in the healthcare sector [17][36] Other Important Information - The company has a strong cash position, with plans to continue building cash reserves while managing debt effectively [46] - The effective tax rate for the quarter was reported at 23.5%, with no anticipated changes [17] Q&A Session Summary Question: Revised tariff estimate details - The increase in tariff expectations was driven by higher tariffs on metals and changes in EU tariffs, leading to an overall increase in tariff exposure [22] Question: Maintaining organic growth expectations for AST - Management indicated that the decision to maintain the 6% to 7% organic growth expectation is based on conservatism despite a strong start [24] Question: Update on bioprocessing market - The bioprocessing market has shown consistent volume over the last few months, indicating a return to normal trajectory [28] Question: Life Sciences segment backlog increase - The increase in backlog is attributed to a recovery in capital orders following a previous slowdown, with strong order intake expected [30] Question: Competitive landscape regarding low temp sterilization - Management expressed confidence in their position and did not observe any slowdown in their operations despite competitor concerns [34] Question: Employee healthcare benefit costs - The increase in costs is primarily due to higher utilization of employee healthcare benefits, with premiums increasing slightly [37] Question: Capital demand environment and order growth - Strong orders in both Healthcare and Life Sciences sectors contribute positively to revenue guidance, with no observed slowdown [41] Question: M&A activity and cash allocation - The company remains active in M&A discussions and plans to continue building cash reserves while considering stock buybacks [43][46] Question: Impact of regulatory changes on EO facilities - The company did not apply for regulatory relief as they are already compliant, and the competitive impact is expected to be minimal [56] Question: Hospital outlook and OB3 impact - Management views the challenges as payment reimbursement issues rather than demand issues, with no observed pullback in procedure volumes [63] Question: FX impact on profitability - The company is largely operationally hedged against FX impacts, with minimal effects on profitability [66] Question: ASC build-out in the US - The relocation of procedures to ASCs is seen as beneficial for capital business, requiring proper training and compliance programs [72]

Financial Data and Key Metrics Changes - The company held its Annual Meeting of Stockholders on June 17, 2025, but specific financial data and key metrics were not disclosed during the meeting [1][2][3] Business Line Data and Key Metrics Changes - No specific data or key metrics related to individual business lines were provided in the meeting [1][2][3] Market Data and Key Metrics Changes - There were no updates or changes reported regarding market data or key metrics during the meeting [1][2][3] Company Strategy and Development Direction and Industry Competition - The company discussed its ongoing commitment to virtual stockholder meetings to enhance access and participation, indicating a focus on shareholder engagement [2][5] - The board of directors recommended several proposals, including the approval of the 2025 Block, Inc. Equity incentive plan, which suggests a strategy to align executive compensation with company performance [11][12] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [1][2][3] Other Important Information - The meeting included procedural matters such as the appointment of an inspector of election and the confirmation of a quorum for conducting business [4][7] - The company confirmed that the final voting results would be reported on a Form 8-K filed with the SEC within four business days [16] Q&A Session Summary - The Q&A session was conducted, but no questions were received from stockholders, leading to the conclusion of the meeting without any discussions [20]

Financial Data and Key Metrics Changes - SWK Holdings reported a GAAP pretax net income of $5.8 million or $0.48 per diluted share for Q1 2025, with a net income of $4.5 million after tax expenses [12] - The non-GAAP tangible book value per share increased to $21.73, a 10.5% rise from $19.66 in Q1 2024 [13] - Overall operating expenses decreased to $3.7 million in Q1 2025 from $10.3 million in Q1 2024, primarily due to a significant reduction in provisions for credit losses [13][14] Business Line Data and Key Metrics Changes - The finance segment adjusted non-GAAP net income for Q1 2025 was $8.6 million, contributing to a trailing twelve-month total of $26 million [5] - The Mod three CDMO division reported segment revenue of $1 million with an EBITDA loss of $0.5 million for Q1 2025 [10] - The finance receivables segment experienced a $300,000 decrease in revenue year-over-year, primarily due to a $2.4 million decrease in interest and fees earned [12] Market Data and Key Metrics Changes - As of March 31, 2025, the gross finance receivables portfolio consisted of approximately $220 million in performing first lien loans and $13 million in non-accruals [6] - The effective yield on the finance receivable portfolio was 14.5%, expected to generate approximately $32 million in annual interest income if repayments occur as modeled [7][9] Company Strategy and Development Direction - The company aims to maintain a high-quality portfolio that can earn mid-teens returns while pursuing additional financing opportunities [8] - Management is focused on simplifying the business and ensuring appropriate returns on equity capital, with plans for a new share repurchase program [5][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the portfolio's strength and noted that ongoing healthcare and economic regulatory changes do not pose significant risks [9] - The current pipeline for loans is considered neutral, with modest opportunities available, particularly for smaller companies struggling to secure capital [48] Other Important Information - The company repurchased approximately 52,000 shares at a total cost of $900,000 during the quarter, with additional repurchases post-quarter [15] - The company holds $5 million in public equities and warrants, as well as private warrants and contingent economic interests carried at zero on the books [6][31] Q&A Session Summary Question: Inquiry about the two loans rated number two on credit - Management confirmed that both are first lien term loans, while three non-accruals are defined as post-reorganization royalties [20][22] Question: Discussion on competition in the private credit space - Management acknowledged increased competition but emphasized the importance of being proactive and creative in proposals to maintain a high-quality portfolio [25][27] Question: Best use of capital at this point - Management indicated that buying back stock is a great use of capital, alongside paying special dividends and selectively pursuing additional loans [44][46] Question: Current pipeline of possible loans compared to previous quarters - Management described the current loan pipeline as neutral, with modestly worse opportunities sequentially compared to the previous year [48]

Core Insights - Ingredion Incorporated reported strong performance in Q1 2025, driven by sales growth across global regions, particularly in clean label solutions, with a 34% increase in operating income for the texture and health solutions segment [1][4][10] - The company has raised its full-year earnings expectations due to the excellent performance in the first quarter, emphasizing its commitment to becoming the preferred choice for customers [1][21] - Despite a 4% decline in net sales compared to Q1 2024, the company achieved a 30% increase in reported operating income and a 26% increase in adjusted operating income [4][10][36] Financial Performance - Reported diluted EPS for Q1 2025 was $3.00, down from $3.23 in Q1 2024, while adjusted diluted EPS increased to $2.97 from $2.08 [2][4] - Total net sales for Q1 2025 were $1.813 billion, a decrease of 4% from $1.882 billion in Q1 2024, primarily due to changes in pricing mix and foreign exchange impacts [6][32] - Operating income for Q1 2025 was $276 million, reflecting a 30% increase from $213 million in Q1 2024, with adjusted operating income also showing a significant increase [10][37] Segment Performance - The texture and health solutions segment reported operating income of $99 million, a 34% increase year-over-year, driven by lower raw material costs and increased sales volume [13][37] - The Latin America food and industrial ingredients segment achieved operating income of $127 million, a 26% increase, benefiting from favorable market conditions and cost reductions [15][37] - The U.S./Canada food and industrial ingredients segment saw a slight increase in operating income to $92 million, up 6% year-over-year, attributed to improved product mix and cost management [17][37] Outlook - The company expects full-year 2025 reported EPS to range between $10.93 and $11.63, with adjusted EPS projected between $10.90 and $11.60, reflecting anticipated sales growth despite potential pricing and foreign exchange challenges [21][23] - For 2025, net sales are expected to achieve low single-digit growth, with operating income projected to grow close to 20% due to last year's impairment charge base effect [21][22] - The company anticipates a moderate increase in costs for the year, with capital expenditures expected to be between $400 million and $450 million [22][23]

Financial Data and Key Metrics Changes - In Q1, the company met the midpoint of its revenue guidance with total revenue of $161 million, reflecting an 8% decline quarter over quarter [17] - The net loss for the quarter was $15.1 million, a 14% improvement compared to the same period in 2024 [17] - Adjusted EBITDA loss for the first quarter was $7.8 million, a sequential improvement of 32% [19] Business Line Data and Key Metrics Changes - The Renovate business generated a record revenue of $5.3 million in Q1, with an annualized run rate of approximately $20 million, marking the highest quarterly total since its launch [6] - The cash offer business remains a key revenue driver, while asset-light services, including Renovate, Direct Plus, and the agent partnership program, contributed over 40% of contribution profit after interest [16][17] Market Data and Key Metrics Changes - Offer requests rose by 33% quarter over quarter, indicating increased consumer interest [9] - The average time to cash for homes sold in Q1 was 165 days, consistent with expectations following acquisition adjustments [17] Company Strategy and Development Direction - The company is focusing on enhancing the customer experience through technology and operational improvements, aiming for positive adjusted EBITDA and sustainable long-term growth [6][13] - A new partnership with Auction.com was announced, positioning Renovate as a preferred provider of renovation services [6] - The company is prioritizing diversification through high-margin revenue streams and disciplined resource management [6][14] Management's Comments on Operating Environment and Future Outlook - Management noted that the housing market is facing sustained macroeconomic pressures, including elevated mortgage rates and affordability challenges, impacting transaction volumes [7][8] - The company anticipates sequential improvements in time to cash and revenue in Q2, with guidance of $160 million to $190 million [20] Other Important Information - The company has made significant progress in reducing annual operating expenses by approximately $115 million over the past 24 months [19] - As of the end of Q1, unrestricted cash totaled $31 million, with total liquidity exceeding $60 million [19] Q&A Session Summary Question: Acquisition pace of homes and seasonal patterns - Management expects increased acquisition volumes in Q2, with a target of 1,000 homes per quarter as a North Star for profitability [27][46] Question: Stability of the current market environment - Management acknowledged market volatility but noted increased opportunities for acquisitions in select areas [33][41] Question: Financial impact of changes made in April - Management indicated that further details on cost reductions would be provided in the next quarter, with ongoing efforts to improve operational efficiency [32][34] Question: Supply-demand dynamics in key markets - Management observed rising inventory levels and emphasized a selective approach to acquisitions based on market conditions [40][41] Question: Contribution margin targets with increased acquisition volume - Management expects contribution margins to improve as more recent purchases are integrated into the portfolio [37]